Media
Corgentech To Present At Bear Stearns 17th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 7, 2004 -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John McLaughlin, the company's president and chief executive officer, will present at the Bear Stearns 17th Annual Healthcare Conference on Monday, September 13, 2004 at 2:45 p.m. EDT at The Plaza Hotel in New York. He will discuss Corgentech's lead product candidate, edifoligide (E2F Decoy), a novel and proprietary transcription factor decoy that is in Phase 3 clinical trials for the prevention of vein graft failure, as well as describe the company's pipeline of product candidates.
To access the live audio webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investor Information page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis and dermatitis, and cancer. For more information on the company and its technology, visit www.corgentech.com.
